Amal M. Johnson - Nov 8, 2022 Form 4 Insider Report for INTUITIVE SURGICAL INC (ISRG)

Role
Director
Signature
By: Donna Spinola For: Johnson, Amal M.
Stock symbol
ISRG
Transactions as of
Nov 8, 2022
Transactions value $
-$1,183,212
Form type
4
Date filed
11/9/2022, 04:17 PM
Previous filing
Sep 9, 2022
Next filing
Dec 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISRG Common Stock Options Exercise $343K +6.38K +56.8% $53.76* 17.6K Nov 8, 2022 Direct F1
transaction ISRG Common Stock Sale -$1.53M -6.38K -36.22% $239.36 11.2K Nov 8, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -6.38K -100% $0.00* 0 Nov 8, 2022 Common Stock 6.38K $53.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 26, 2023.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $237.71 to $242.18 as follows: 3,103 shares sold at $237.71 - $238.69; 1,704 shares sold at $238.77 - $239.64; 390 shares sold at $239.85 - $240.79; and 1,178 shares sold at $241.46 - $242.18. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.